Concentration-dependent protein adsorption at the nano–bio interfaces of polymeric nanoparticles and serum proteins

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Tomcin S, Kelsch A, Staff RH, Landfester K, Zentel R, Mailander V. HPMA-based block copolymers promote differential drug delivery kinetics for hydrophobic and amphiphilic molecules. Acta Biomater. 35, 12–22 (2016).
  Medline CASGoogle Scholar
• 2 He H, Zhang J, Xie Y et al. Bioimaging of intravenous polymeric micelles based on discrimination of integral particles using an environment-responsive probe. Mol. Pharm. 13(11), 4013–4019 (2016).
  Medline CASGoogle Scholar
• 3 Gao J, Li W, Guo Y, Feng SS. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine (London, UK) 11(24), 3261–3282 (2016).
  CASGoogle Scholar
• 4 Zhang T, Zhu G, Lu B, Peng Q. Oral nano-delivery systems for colon targeting therapy. Pharm. Nanotechnol. 5(2), 83–94 (2017).
  Medline CASGoogle Scholar
• 5 Do Nascimento TG, Da Silva PF, Azevedo LF et al. Polymeric nanoparticles of Brazilian red propolis extract: preparation, characterization, antioxidant and leishmanicidal activity. Nanoscale Res. Lett. 11(1), 301 (2016).
  MedlineGoogle Scholar
• 6 Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv. Drug Deliv. Rev. 64(13), 1363–1384 (2012).
  Medline CASGoogle Scholar
• 7 Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41(7), 2780–2799 (2012). • Comprehensive review of nano–bio interactions.
  Medline CASGoogle Scholar
• 8 Qi J, Zhuang J, Lu Y, Dong X, Zhao W, Wu W. In vivo fate of lipid-based nanoparticles. Drug Discov. Today 22(1), 166–172 (2017).
  Medline CASGoogle Scholar
• 9 Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7(12), 779–786 (2012). •• Excellent review of nanoparticle corona formation and its biological impacts.
  Medline CASGoogle Scholar
• 10 Wei XQ, Hao LY, Shao XR et al. Insight into the interaction of graphene oxide with serum proteins and the impact of the degree of reduction and concentration. ACS Appl. Mater. Interfaces 7(24), 13367–13374 (2015).
  Medline CASGoogle Scholar
• 11 Sobczynski DJ, Eniola-Adefeso O. Effect of anticoagulants on the protein corona-induced reduced drug carrier adhesion efficiency in human blood flow. Acta Biomater. 48, 186–194 (2017).
  Medline CASGoogle Scholar
• 12 Wang Z, Wang C, Liu S et al. Specifically formed corona on silica nanoparticles enhances transforming growth factor beta1 activity in triggering lung fibrosis. ACS Nano 11(2), 1659–1672 (2017).
  Medline CASGoogle Scholar
• 13 Di Silvio D, Maccarini M, Parker R, Mackie A, Fragneto G, Baldelli Bombelli F. The effect of the protein corona on the interaction between nanoparticles and lipid bilayers. J. Colloid Interface Sci. 504, 741–750 (2017).
  Medline CASGoogle Scholar
• 14 Peng Q, Zhang S, Yang Q et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials 34(33), 8521–8530 (2013). • Example of how to use protein adsorption for controlled drug delivery.
  Medline CASGoogle Scholar
• 15 Peng Q, Wei XQ, Yang Q et al. Enhanced biostability of nanoparticle-based drug delivery systems by albumin corona. Nanomedicine (London, UK) 10(2), 205–214 (2015).
  CASGoogle Scholar
• 16 Li Y, Monteiro-Riviere NA. Mechanisms of cell uptake, inflammatory potential and protein corona effects with gold nanoparticles. Nanomedicine (London, UK) 11(24), 3185–3203 (2016).
  CASGoogle Scholar
• 17 Sangra M, Estelrich J, Sabate R, Espargaro A, Busquets MA. Evidence of protein adsorption in pegylated liposomes: influence of liposomal decoration. Nanomaterials (Basel, Switzerland) 7(2), 37 (2017).
  Google Scholar
• 18 Salvati A, Pitek AS, Monopoli MP et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8(2), 137–143 (2013). •• Typical evidence of negative effect of protein corona on nanoparticles delivery.
  Medline CASGoogle Scholar
• 19 Peng Q, Mu H. The potential of protein-nanomaterial interaction for advanced drug delivery. J. Control. Release 225, 121–132 (2016). • Comprehensive review of protein corona formation and its potential for advanced drug delivery.
  Medline CASGoogle Scholar
• 20 Mirshafiee V, Kim R, Park S, Mahmoudi M, Kraft ML. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 75, 295–304 (2016).
  Medline CASGoogle Scholar
• 21 Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (London, UK) 11(1), 81–100 (2016). • Clear example of biological impacts of protein corona.
  CASGoogle Scholar
• 22 Chen F, Wang G, Griffin JI et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotechnol. 12(4), 387–393 (2017). •• Excellent example of dynamic exchange of protein adsorption in vivo.
  Medline CASGoogle Scholar
• 23 Shemetov AA, Nabiev I, Sukhanova A. Molecular interaction of proteins and peptides with nanoparticles. ACS Nano 6(6), 4585–4602 (2012).
  Medline CASGoogle Scholar
• 24 Yang ST, Liu Y, Wang YW, Cao A. Biosafety and bioapplication of nanomaterials by designing protein-nanoparticle interactions. Small 9(9–10), 1635–1653 (2013).
  Medline CASGoogle Scholar
• 25 Ajdari N, Vyas C, Bogan SL, Lwaleed BA, Cousins BG. Gold nanoparticle interactions in human blood: a model evaluation. Nanomed. Nanotechnol. Biol. Med. 13(4), 1531–1542 (2017).
  CASGoogle Scholar
• 26 Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 151(2), 458–465 (2010).
  Medline CASGoogle Scholar
• 27 Moghimi SM. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J. Control. Release 190, 556–562 (2014).
  Medline CASGoogle Scholar
• 28 Lindman S, Lynch I, Thulin E, Nilsson H, Dawson KA, Linse S. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett. 7(4), 914–920 (2007).
  Medline CASGoogle Scholar
• 29 Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265–14270 (2008).
  Medline CASGoogle Scholar
• 30 Ma Z, Bai J, Wang Y, Jiang X. Impact of shape and pore size of mesoporous silica nanoparticles on serum protein adsorption and RBCs hemolysis. ACS Appl. Mater. Interfaces 6(4), 2431–2438 (2014).
  Medline CASGoogle Scholar
• 31 Shang L, Nienhaus GU. In situ characterization of protein adsorption onto nanoparticles by fluorescence correlation spectroscopy. Acc. Chem. Res. 50(2), 387–395 (2017).
  Medline CASGoogle Scholar
• 32 Koshkina O, Lang T, Thiermann R et al. Temperature-triggered protein adsorption on polymer-coated nanoparticles in serum. Langmuir 31(32), 8873–8881 (2015).
  Medline CASGoogle Scholar
• 33 Foroozandeh P, Aziz AA. Merging worlds of nanomaterials and biological environment: factors governing protein corona formation on nanoparticles and its biological consequences. Nanoscale Res. Lett. 10, 221 (2015).
  MedlineGoogle Scholar
• 34 Mahmoudi M, Abdelmonem AM, Behzadi S et al. Temperature: the ‘ignored’ factor at the NanoBio interface. ACS Nano 7(8), 6555–6562 (2013).
  Medline CASGoogle Scholar
• 35 Peng Q, Yang YJ, Zhang T et al. The implantable and biodegradable PHBHHx 3D scaffolds loaded with protein-phospholipid complex for sustained delivery of proteins. Pharm. Res. 30(4), 1077–1085 (2013).
  Medline CASGoogle Scholar
• 36 Wu LP, Wang D, Parhamifar L, Hall A, Chen GQ, Moghimi SM. Poly(3-hydroxybutyrate-co-R-3-hydroxyhexanoate) nanoparticles with polyethylenimine coat as simple, safe, and versatile vehicles for cell targeting: population characteristics, cell uptake and intracellular trafficking. Adv. Healthc. Mater. 3(6), 817–824 (2014).
  Medline CASGoogle Scholar
• 37 Shao XR, Wei XQ, Song X et al. Independent effect of polymeric nanoparticle zeta potential/surface charge, on their cytotoxicity and affinity to cells. Cell Prolif. 48(4), 465–474 (2015).
  Medline CASGoogle Scholar
• 38 El-Habashy SE, Allam AN, El-Kamel AH. Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation. Int. J. Nanomed. 11, 2369–2380 (2016).
  Medline CASGoogle Scholar
• 39 Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials 33(5), 1583–1588 (2012).
  Medline CASGoogle Scholar
• 40 He SN, Li YL, Yan JJ et al. Ternary nanoparticles composed of cationic solid lipid nanoparticles, protamine, and DNA for gene delivery. Int. J. Nanomed. 8, 2859–2869 (2013).
  MedlineGoogle Scholar
• 41 Peng Q, Zhang ZR, Sun X, Zuo J, Zhao D, Gong T. Mechanisms of phospholipid complex loaded nanoparticles enhancing the oral bioavailability. Mol. Pharm. 7(2), 565–575 (2010).
  Medline CASGoogle Scholar
• 42 O'connell DJ, Bombelli FB, Pitek AS, Monopoli MP, Cahill DJ, Dawson KA. Characterization of the bionano interface and mapping extrinsic interactions of the corona of nanomaterials. Nanoscale 7(37), 15268–15276 (2015).
  MedlineGoogle Scholar
• 43 Winzen S, Schoettler S, Baier G et al. Complementary analysis of the hard and soft protein corona: sample preparation critically effects corona composition. Nanoscale 7(7), 2992–3001 (2015).
  Medline CASGoogle Scholar
• 44 Ritz S, Schottler S, Kotman N et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 16(4), 1311–1321 (2015).
  Medline CASGoogle Scholar
• 45 Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. Protein-nanoparticle interactions: opportunities and challenges. Chem. Rev. 111(9), 5610–5637 (2011).
  Medline CASGoogle Scholar
• 46 Monopoli MP, Walczyk D, Campbell A et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133(8), 2525–2534 (2011).
  Medline CASGoogle Scholar
• 47 Hajipour MJ, Raheb J, Akhavan O et al. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale 7(19), 8978–8994 (2015).
  Medline CASGoogle Scholar
• 48 Corbo C, Molinaro R, Tabatabaei M, Farokhzad OC, Mahmoudi M. Personalized protein corona on nanoparticles and its clinical implications. Biomater. Sci. 5(3), 378–387 (2017).
  Medline CASGoogle Scholar
• 49 Azhdarzadeh M, Saei AA, Sharifi S et al. Nanotoxicology: advances and pitfalls in research methodology. Nanomedicine (London, UK) 10(18), 2931–2952 (2015).
  CASGoogle Scholar